Prevalence of SCLC in the US and Globally
Qian Wang, MD, MPH, discusses the changing incidence of small cell lung cancer among patients globally and in the United States.
Qian Wang, MD, MPH, assistant professor at Case Western Reserve University, thoracic oncologist at University Hospital Seidman Cancer Center, discusses the changing incidence of small cell lung cancer (SCLC) among patients globally and in the United States.
According to Wang, SCLC accounts for approximately 50% of all cases of lung cancer, and lung cancer as a whole remains the leading cause of cancer related death in male patients.
One of the predominant reasons and highest risk factors a patient develops lung cancer is due to smoking. Though the Tobacco Control Program was initiated in the 1960s and has helped the incidence of lung cancers decline globally, experts in a review published in the Journal of Thoracic Oncology emphasize the importance of continuing efforts in tobacco control worldwide.
Transcription:
0:08 | We know that small cell lung cancer accounts for about 50% of all lung cancer cases. Most of the epidemiological studies combine all small cell and non–small cell lung cancers as 1 group. The incidence and mortality data are both combined, and from looking globally in 2020, we know that lung cancer remains the second most common cancer in males, and the third most common cancer in females. It continues to be a leading cause of cancer-related death in males, and then is the second for females. Approximately in 2020, there were about 1.4 million lung cancer cases in males globally… Among those, approximately 15% of them are small cell lung cancers.
1:05 | Smoking is the predominant cause of lung cancer, especially for small cell lung cancer. The incidence and the mortality lags about 20-30 years years behind the trends in smoking rate. In about the 1960s, the United States and some other countries around the world started and initiated the Tobacco Control Program. After that, around in the late 1980s or 1990s, the smoking incidence and the lung cancer incidence started to [decline], including small cell lung cancer. This is also the same in the United States.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
FDA Grants Breakthrough Status to Sacituzumab Govitecan in ES-SCLC
December 17th 2024The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum chemotherapy, supported by promising antitumor activity in the phase 2 TROPiCS-03 study.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
